Rua Bioscience (NZSE:RUA) Debt-to-Asset : 0.07 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Rua Bioscience Debt-to-Asset?

Rua Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NZ$0.44 Mil. Rua Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NZ$0.07 Mil. Rua Bioscience's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NZ$7.72 Mil. Rua Bioscience's debt to asset for the quarter that ended in Dec. 2024 was 0.07.

Rua Bioscience Debt-to-Asset Historical Data

The historical data trend for Rua Bioscience's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rua Bioscience Debt-to-Asset Chart

Rua Bioscience Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

0.04

0.03

0.01

0.02

Rua Bioscience Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial				0.01	0.01	0.02	0.02	0.07

Competitive Comparison of Rua Bioscience's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rua Bioscience's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rua Bioscience's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Rua Bioscience Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rua Bioscience's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.049	+	0.099)	/	7.74
	=	0.02

Rua Bioscience's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.44	+	0.073)	/	7.722
	=	0.07

Rua Bioscience (NZSE:RUA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rua Bioscience Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rua Bioscience's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rua Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rua Bioscience Ltd (NZSE:RUA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Commerce Place, Awapuni, Gisborne, NZL, 4071

Website

https://www.ruabio.com

Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany and New Zealand.

Rua Bioscience Headlines

No Headlines